Hospital
SSM Health Care of Oklahoma, INC.
SSM Health Care of Oklahoma, INC. was paid $46.86M by Medicaid between Jan 2018 and Dec 2024, across 182 billing codes. Its largest line is 99283, emergency room visit (moderate) — 32% of everything it billed.
33Billing provider infoSSM HEALTH CARE OF OKLAHOMA, INC.
OKLAHOMA CITY, OK 73102
OKLAHOMA CITY, OK 73102
33aNPI1366545311assigned 09/06/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$46.86M
24GClaims614,015
24DCodes billed182
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Oklahoma
Rank by total paid#1 of 75
Median peer was paid$3.66M
This provider vs. median13×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MANUEL, SHASTA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 49,714 | $3.73M | |
| 2019 | 47,289 | $3.86M | |
| 2020 | 40,361 | $3.03M | |
| 2021 | 91,188 | $6.08M | |
| 2022 | 142,453 | $11.15M | |
| 2023 | 161,058 | $12.02M | |
| 2024incomplete | 81,952 | $6.99M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 32% | 94,850 | 94,199 | $15.20M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 24% | 45,956 | 45,671 | $11.14M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 9.0% | 45,516 | 45,255 | $4.20M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 7.0% | 23,829 | 23,535 | $3.29M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.8% | 8,880 | 8,839 | $3.17M |
| J3490 | Unclassified drugs | 2.3% | 25,417 | 19,464 | $1.09M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.2% | 7,908 | 7,890 | $1.05M |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | 1.7% | 4,993 | 356 | $799K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 11,712 | 11,462 | $558K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,412 | 5,286 | $412K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,810 | 5,740 | $390K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,477 | 2,152 | $381K |
170 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 57,719 | $373K |
| 80053 | Comprehensive metabolic panel | <1% | 32,590 | $357K |
| J0490 | Injection, belimumab, 10 mg | <1% | 283 | $343K |
| 36415 | Collection of venous blood by venipuncture | <1% | 28,922 | $294K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,695 | $287K |
| 71045 | Radiologic examination, chest; single view | <1% | 17,099 | $230K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 5,779 | $225K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 65 | $191K |
| 64493 | <1% | 434 | $179K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 8,680 | $119K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,456 | $105K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 314 | $102K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,320 | $101K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,468 | $101K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,963 | $92K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,648 | $87K |
| 86235 | <1% | 1,324 | $86K | |
| 64483 | <1% | 208 | $85K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,342 | $78K |
| 81025 | <1% | 10,341 | $78K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 789 | $78K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,353 | $76K |
| 64635 | <1% | 90 | $76K | |
| 84484 | <1% | 4,218 | $72K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 952 | $71K |
| 80050 | General health panel | <1% | 2,046 | $60K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 799 | $60K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 15 | $57K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 316 | $55K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 528 | $53K |
| 87480 | <1% | 2,476 | $47K | |
| 87660 | <1% | 2,453 | $46K | |
| 87510 | <1% | 2,448 | $46K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,584 | $45K |
| 81001 | <1% | 15,476 | $44K | |
| 80061 | Lipid panel | <1% | 3,785 | $42K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 185 | $41K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,884 | $40K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 50 | $38K |
| 95816 | <1% | 152 | $36K | |
| 83690 | <1% | 5,959 | $34K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 52 | $33K |
| 80074 | <1% | 758 | $32K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 66 | $31K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 621 | $29K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 626 | $28K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,912 | $28K |
| 86140 | <1% | 5,599 | $22K | |
| 87070 | <1% | 2,728 | $21K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,010 | $21K |
| 86160 | <1% | 1,060 | $16K | |
| 83735 | <1% | 3,026 | $16K | |
| 96415 | <1% | 283 | $15K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,774 | $14K |
| 80055 | <1% | 346 | $14K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 862 | $13K |
| 64490 | <1% | 26 | $12K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 113 | $11K |
| 85652 | <1% | 5,037 | $10K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 788 | $10K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 38 | $9K |
| 86803 | <1% | 710 | $8K | |
| 86480 | <1% | 166 | $8K | |
| 86225 | <1% | 710 | $7K | |
| 62323 | <1% | 19 | $7K | |
| 86200 | <1% | 701 | $7K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 40 | $7K |
| 83605 | <1% | 537 | $6K | |
| 95811 | <1% | 15 | $6K | |
| 73130 | <1% | 195 | $5K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 68 | $5K |
| 88313 | <1% | 43 | $4K | |
| G0260 | Injection procedure for sacroiliac joint; provision of anesthetic, steroid and/or other therapeutic agent, with or without arthrography | <1% | 13 | $4K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,445 | $4K |
| 86039 | <1% | 476 | $4K | |
| 85651 | <1% | 993 | $4K | |
| 86850 | <1% | 330 | $4K | |
| 87150 | <1% | 118 | $4K | |
| 81003 | <1% | 1,533 | $4K | |
| 84703 | <1% | 427 | $3K | |
| 83880 | <1% | 93 | $3K | |
| 84481 | <1% | 190 | $3K | |
| 84439 | <1% | 373 | $3K | |
| 72100 | <1% | 114 | $2K | |
| 85027 | <1% | 455 | $2K | |
| 73630 | <1% | 132 | $2K | |
| 86430 | <1% | 530 | $2K | |
| 87807 | <1% | 199 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,692 | $2K |
| 88142 | <1% | 145 | $2K | |
| 0002A | <1% | 50 | $2K | |
| 0001A | <1% | 48 | $2K | |
| 82728 | <1% | 162 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 68 | $2K |
| 86780 | <1% | 270 | $2K | |
| 82950 | <1% | 362 | $2K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 43 | $1K |
| 72202 | <1% | 54 | $1K | |
| 84466 | <1% | 125 | $1K | |
| 93880 | <1% | 12 | $1K | |
| 71271 | <1% | 12 | $1K | |
| 96367 | <1% | 23 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 112 | $1K |
| 71250 | <1% | 24 | $1K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 12 | $1K |
| 86592 | <1% | 266 | $969.00 | |
| 86900 | <1% | 343 | $892.25 | |
| 87081 | <1% | 150 | $873.39 | |
| 88304 | <1% | 26 | $871.95 | |
| 87653 | <1% | 28 | $850.32 | |
| 83970 | <1% | 40 | $812.04 | |
| 86762 | <1% | 87 | $768.00 | |
| 73523 | <1% | 25 | $761.00 | |
| 80047 | <1% | 67 | $743.47 | |
| 85610 | <1% | 195 | $699.06 | |
| 80306 | <1% | 53 | $698.04 | |
| 82570 | <1% | 170 | $697.06 | |
| 86901 | <1% | 320 | $689.85 | |
| 83540 | <1% | 136 | $684.75 | |
| 86787 | <1% | 53 | $561.54 | |
| 87340 | <1% | 86 | $560.59 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 413 | $557.77 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 217 | $556.53 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 20 | $520.74 |
| 82043 | <1% | 110 | $487.33 | |
| 84550 | <1% | 132 | $457.26 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 1,295 | $455.46 |
| 82550 | <1% | 91 | $452.28 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 152 | $440.85 |
| 82274 | <1% | 31 | $386.96 | |
| 73110 | <1% | 24 | $359.64 | |
| 83516 | <1% | 12 | $338.58 | |
| 80076 | <1% | 47 | $323.60 | |
| 76000 | <1% | 15 | $322.26 | |
| 73562 | <1% | 13 | $295.40 | |
| 86812 | <1% | 12 | $275.52 | |
| 84156 | <1% | 64 | $275.08 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 10,065 | $273.96 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,402 | $260.31 |
| 83655 | <1% | 24 | $258.48 | |
| 82962 | <1% | 77 | $233.60 | |
| 81002 | <1% | 64 | $192.20 | |
| 82785 | <1% | 13 | $190.32 | |
| 86800 | <1% | 13 | $183.95 | |
| 86376 | <1% | 13 | $168.22 | |
| 84702 | <1% | 12 | $160.68 | |
| 85018 | <1% | 52 | $110.60 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 949 | $100.00 |
| 84100 | <1% | 41 | $93.56 | |
| 85014 | <1% | 40 | $87.39 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,670 | $85.27 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 12 | $75.95 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 88 | $46.10 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 687 | $42.87 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 93 | $33.46 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,578 | $20.44 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 12 | $11.95 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 30 | $9.70 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 817 | $1.64 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,113 | $1.35 |
| 91300 | 0% | 180 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 37 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 183 | $0.00 |
| C1776 | Joint device (implantable) | 0% | 12 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 12 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 302 | $0.00 |
| A4300 | Implantable access catheter, (e.g., venous, arterial, epidural subarachnoid, or peritoneal, etc.) external access | 0% | 120 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 53 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 13 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMANUEL, SHASTA (REGIONAL VP - FINANCE)
| Provider | Location | Paid |
|---|---|---|
| ST Anthony Shawnee Hospital INC | Shawnee, OK | $23.00M |
| Saints Medical Group, LLC | Shawnee, OK | $14.52M |
| Saint Medical Group, LLC | Shawnee, OK | $4.51M |
| SSM Regional Health Services | Jefferson City, MO | $2.49M |
| Saints Medical Group, LLC | Shawnee, OK | $1.32M |
| SSM Regional Health Services | Jefferson City, MO | $1.26M |
| SSM Health Care of Oklahoma, INC. | Oklahoma City, OK | $856K |
| SSM Regional Health Services | Jefferson City, MO | $842K |
| SSM Regional Health Services | Jefferson City, MO | $398K |
| SSM Regional Health Services | Belle, MO | $388K |
| SSM Regional Health Services | Tipton, MO | $304K |
| SSM Health Care of Oklahoma, INC | Oklahoma City, OK | $269K |
| Saint Medical Group, LLC | Tecumseh, OK | $246K |
| SSM Regional Health Services | Jefferson City, MO | $239K |
| Saint Medical Group, LLC | Chandler, OK | $194K |
| SSM Regional Health Services | Jefferson City, MO | $191K |
| Saints Medical Group, LLC | Okemah, OK | $165K |
| SSM Regional Health Services | Jefferson City, MO | $149K |
| Saints Medical Group, LLC | Oklahoma City, OK | $84K |
| SSM Regional Health Services | Jefferson City, MO | $61K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.